Jazz Pharmaceuticals Announces Third Quarter 2009 Financi...($25038 $14234 $65119 $37980 Luvox CR ...),Health

Date:11/5/2009

$25,038 $14,234 $65,119 $37,980 Luvox CR 4,954 1,957 12,670 2,671 Antizol and Antizol-Vet (1) - 831 - 5,106 - --- - ----- Total $29,992 $17,022 $77,789 $45,757 ======= ======= ======= ======= (1) The Company sold its rights to and interests in Antizol and Antizol-Vet in August 2008. JAZZ PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) September 30, December 31, 2009 2008 ---- ---- ASSETS Current assets: Cash and cash equivalents $12,230 $24,903 Restricted cash 950 1,913 Marketable securities - 1,004 Accounts receivable 9,202 6,643 Inventories 4,532 4,788 Prepaid expenses 1,969 2,366 Other current assets 261 2,382 --- ----- Total current assets 29,144 43,999 Property and equipment, net 1,444 2,514 Intangible assets, net 31,915 32,526 Goodwill 38,213 38,213 Other long-term assets 1,456 246
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate